이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

재발성 또는 불응성 림프종 또는 불명확한 클론성 혈구감소증 치료를 위한 아스코르브산 및 병용 화학요법

2026년 9월 24일 업데이트: Mayo Clinic

LS1781 재발성/불응성 림프종 및 불명확한 클론성 혈구감소증 환자에서 구제 화학 요법의 보조제로서 고용량 아스코르브산 정맥 주사의 2상 시험

This phase II trial studies the effect of ascorbic acid and combination chemotherapy in treating patients with lymphoma that has come back (recurrent) or does not respond to therapy (refractory), clonal cytopenia of undetermined significance and chronic myelomonocytic leukemia (CMML). Ascorbic acid may make cancer cells more sensitive to chemotherapy. Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ascorbic acid and combination chemotherapy may kill more cancer cells.

Arms A, B, C, and D are closed to enrollment.

연구 개요

상세 설명

PRIMARY OBJECTIVES:

I. To determine the overall response rate (ORR) at the end of 2 cycles for intravenous (IV) ascorbic acid (AA) added to standard salvage therapy compared to standard salvage therapy plus normal saline in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who have relapsed within the first 24 months of end of their therapy. [Arms A versus (vs) B] II. To determine the ORR at the end of 2 cycles of AA plus standard salvage chemotherapy in patients with other types of relapsed/refractory lymphomas not eligible for Arms A/B [peripheral T-cell lymphoma (PTCL), double-hit high grade, and Hodgkin lymphoma (HL)]. (Arm C) III. To assess the hematological response rate to treatment with high dose intravenous ascorbic acid (IV AA) for clonal cytopenia of undetermined significance (CCUS) patients. (Arm D) IV. To assess the hematological response rate to treatment with high dose intravenous ascorbic acid (IV AA) for CCUS patients. (Arm E)

SECONDARY OBJECTIVES:

I. To compare the adverse event profile of IV AA added to salvage therapy versus salvage therapy plus IV saline in patients with DLBCL using both the Common Terminology Criteria for Adverse Events (CTCAE) and Patient-Reported Outcomes (PRO)-CTCAE. (Arms A and B) II. To compare the progression-free survival, overall survival, clinical benefit rate (those not progressing), and percentage (%) transplant eligible patients proceeding to transplant of AA added to salvage therapy versus salvage therapy plus IV saline in patients with DLBCL. (Arms A and B) III. To compare the ORR at the end of 4 cycles for those with minor response/stable disease at the end of cycle 2 who proceed to receive the additional 2 cycles of rituximab, dexamethasone, cytarabine and cisplatin (RDHAP) with either AA or normal saline (NS) as previously assigned. (Arms A and B) IV. To evaluate the adverse event profile, rate of febrile neutropenia, overall survival, progression-free survival, and clinical benefit rate of AA added to salvage therapy in patients with relapsed/refractory lymphoma. (Arm C) V. To assess safety/tolerability, transfusion dependency (TD), progression-free survival (PFS), and overall survival (OS) for CCUS patients receiving high dose IV AA. (Arm D) VI. To define CR, complete cytogenetic remission, partial remission, marrow response, and clinical benefit response rates. (Arm E) VII. To determine clinical benefit response rates of erythroid response, platelet response, neutrophil response, spleen response and symptom response as adjudicated by the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) total symptom scoring system. (Arm E)

EXPLORATORY OBJECTIVES:

I. Will include baseline AA levels [at Mayo Clinic Research (MCR)] and staining of pre/post treatment biopsies for markers of oxidative stress generation and deoxyribonucleic acid (DNA) methylation. (Arms A, B, and C Correlative Research on blood and tumor tissue) IIa. To assess TET2 activity at baseline, weeks 12, 20, and 52. (Arm D correlative research) IIb. To assess the association between using AA and the hydroxymethylation and methylation status (gene-specific and global changes in 5mC/5hmC level) at baseline and weeks 20 and 52. (Arm D correlative research) IIc. To assess the association between using IV AA and endothelial dysfunction (at baseline, weeks 20, and 52). (Arm D correlative research) IId. To assess the association between using IV AA and the inflammation markers. (Arm D correlative research) IIe. To assess the association between using IV AA and molecular response including clonal dynamics [new mutations and variant allele frequency (VAF)] (at baseline, weeks 20, and 52). (Arm D correlative research)

III. Correlative studies will assess impact on:

IIIa. Somatic mutational allele burdens after 4 cycles of therapy; IIIb. DNA methylation and hydroxymethylation after 4 cycles of therapy; IIIc. Inflammatory cytokines; IIId. Colony forming assay growth and differentiation; IIIe. Methylation at the single colony level; IIIf. Single cell methylation, transcription, and somatic mutations. (Arm E correlative research)

OUTLINE: Patients with DLBCL are randomized to Arms A or B. Patients with other lymphomas are assigned to Arm C. Patients with CCUS are assigned to Arm D. Patients with TET2 mutant CMML are assigned to ARM E.

Arm A (CLOSED): Patients receive ascorbic acid IV on days 1, 3, 5, 8, 10, 12, 15, 17, and 19, and rituximab intravenously (IV), ifosfamide IV, carboplatin IV and etoposide IV on days 1-3. Patients who achieve minor response (MR) or stable disease (SD) after 2 cycles may receive rituximab IV or PO, cisplatin IV or PO, cytarabine IV or PO, and dexamethasone IV or PO. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.

ARM B (CLOSED): Patients receive placebo (normal saline) IV on days 1, 3, 5, 8, 10, 12, 15, 17, and 19, and rituximab intravenously IV, ifosfamide IV, carboplatin IV and etoposide IV on days 1-3. Patients who achieve MR or SD after 2 cycles may receive rituximab IV or PO, cisplatin IV or PO, cytarabine IV or PO, and dexamethasone IV or PO. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.

ARM C (CLOSED): Patients receive ascorbic acid IV on days 1, 3, 5, 8, 10, 12, 15, 17, and 19. Patients also receive ifosfamide, carboplatin, and etoposide IV or PO, or cisplatin, cytarabine, and dexamethasone IV or PO, or gemcitabine hydrochloride, dexamethasone, and cisplatin IV or PO, or gemcitabine hydrochloride and oxaliplatin IV or PO, or oxaliplatin, cytarabine, and dexamethasone IV or PO according to standard regimen schedule. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve MR or SD after 2 cycles may switch to an alternative chemotherapy regimen.

ARM D (CLOSED): Patients receive ascorbic acid IV three times a week (TIW). Treatments repeat every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.

ARM E: Patients receive ascorbic acid IV on days 1, 3 and 5 and decitabine IV over 1 hour or decitabine and cedazuridine PO on days 1-5. Treatment repeats every 35 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients with stable disease after 12 cycles may continue decitabine with or without ascorbic acid as long as clinically appropriate. Patients may also take vitamin C PO on days 6-28.

In Arms A, B, and C, patients who achieve complete response (CR), partial response (PR) or MR may undergo stem cell transplantation. Patients additionally, undergo blood sample collection, core needle biopsy, bone marrow aspiration and biopsy, echocardiography (ECHO), positron emission tomography (PET)/ computed tomography (CT) or magnetic resonance imaging (MRI) throughout study.

Patients in ARM D and E undergo peripherally inserted central catheter (PICC) or portacath placement prior to starting treatment, blood sample collection, bone marrow aspiration and biopsy throughout study.

After completion of study treatment, patients are followed up every 3 months, then every 6 months after progressive disease for up to 2 years.

연구 유형

중재적

등록 (추정된)

80

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • Minnesota
      • Mankato, Minnesota, 미국, 56001
        • 아직 모집하지 않음
        • Mayo Clinic Health Systems-Mankato
        • 수석 연구원:
          • Stephan D. Thome, M.D.
        • 연락하다:
      • Rochester, Minnesota, 미국, 55905
        • 모병
        • Mayo Clinic in Rochester
        • 수석 연구원:
          • Thomas E. Witzig, M.D.
        • 연락하다:
    • Wisconsin
      • Eau Claire, Wisconsin, 미국, 54701
        • 아직 모집하지 않음
        • Mayo Clinic Health System-Eau Claire Clinic
        • 연락하다:
        • 수석 연구원:
          • Eyad S. Al-Hattab, M.D.
      • La Crosse, Wisconsin, 미국, 54601
        • 모집하지 않고 적극적으로
        • Mayo Clinic Health System-Franciscan Healthcare

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Age >= 18 years

  • Biopsy-proven relapsed or refractory lymphomas; relapsed is defined as a relapse that occurred after having a response to the last therapy that lasted > 6 months; refractory is no response or relapse within 6 months; previous biopsies < 6 months prior to treatment on this protocol will be acceptable

    • NOTE: Arms A/B - relapsed or refractory DLBCL within 24 months from the end of anthracycline-based therapy; no prior salvage therapy; patients can have received radiation therapy as part of initial treatment but not specifically for relapse
    • NOTE: Arm C patients include relapsed or refractory lymphoma patients of any type for which the recommended treatment includes one of the platinum-based regimens; of note, relapsed or refractory double-hit high grade lymphoma patients and relapsed or refractory Hodgkin lymphoma patients will be enrolled in Arm C; there is no limit on the number of prior therapies for Arm C patients; the patient must be eligible for a platinum-based regimen and must not have received the same regimen in the past without responding
  • Measurable or assessable disease: measurable disease is defined as measurable by computed tomography (CT) [dedicated CT or the CT portion of a positron emission tomography (PET)/CT] or magnetic resonance imaging (MRI): to be considered measurable, there must be at least one lesion that has a single diameter of >= 1.5 cm

    • NOTE: Skin lesions can be used if the area is >= 1.5 cm in at least one diameter and photographed with a ruler; patients with assessable disease by PET are also eligible as long as the assessable disease is biopsy proven lymphoma
  • Arms A/B - eligible for treatment with ifosfamide, carboplatin, and etoposide (+/- rituximab)

  • Arm C eligible for treatment with one of the following standard, every 3 week, platinum-based salvage regimens (with or without monoclonal antibody as appropriate for the disease):

    • Ifosfamide/carboplatin/etoposide (ICE) or rituximab/ifosfamide/carboplatin/etoposide (RICE);
    • Cisplatin, cytarabine (cytosine arabinoside), dexamethasone (DHAP) or RDHAP;
    • Gemcitabine hydrochloride (gemcitabine), dexamethasone, cisplatin (GDP) or rituximab, gemcitabine, dexamethasone, cisplatin (RGDP);
    • Gemcitabine and oxaliplatin (GemOx) or rituximab, gemcitabine and oxaliplatin (RGemOx);
    • Oxaliplatin, cytosine arabinoside, dexamethasone (OAD) or rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD)
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2

  • Hemoglobin >= 8.0 g/dL (may transfuse to meet this requirement), obtained =< 14 days prior to registration

  • Absolute neutrophil count (ANC) >= 1500/mm^3, obtained =< 14 days prior to registration

  • Platelet count >= 75000/mm^3, obtained =< 14 days prior to registration

  • Total bilirubin =< 2 x upper limit of normal (ULN) (if > 2 x ULN direct bilirubin is required and should be =< 1.5 x ULN), obtained =< 14 days prior to registration

  • Alanine aminotransferase (ALT) and aspartate transaminase (AST) =< 3 x ULN (=< 5 x ULN for patients with liver involvement), obtained =< 14 days prior to registration

  • Creatinine =< 1.6 mg/dL; if over 1.6 then the calculated creatinine clearance must be >= 55 ml/min using the Cockcroft-Gault formula, obtained =< 7 days prior to registration

  • Negative pregnancy test done =< 7 days prior to registration, for persons of childbearing potential only

    • NOTE: If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
  • Human immunodeficiency virus (HIV) test done =< 14 days prior to registration

    • If positive, the CD4 count must be > 400
  • Provide written informed consent

  • Willingness to have a central venous line [peripherally inserted central catheter (PICC) or PORT]

  • Willingness to provide mandatory blood specimens for correlative research

  • Willingness to provide mandatory tissue specimens for correlative research

  • Willingness to return to enrolling institution for follow-up (during the active monitoring phase of the study)

  • Willingness to follow the requirements of the intravenous ascorbic acid program schedule

  • ARM D: Patients who had a diagnosis of CCUS with one or more TET2 mutations or TET2 mutations with concurrent splicing genes mutations (SRSF2, U2AF1, SF3B1, and ZRSR2) or epigenetic regulator mutations (DNMT3A, EZH2, IDH1, IDH2). CCUS diagnosis being defined based on the absence of definitive morphologic evidence of hematologic neoplasms from bone marrow biopsy evaluation combined with evidence of pathogenic myeloid somatic mutation with a variant allele frequency (VAF) of at least 2% using our institution's next generation sequencing (NGS) panel (OncoHeme, Mayo Clinic)

  • ARM D: ECOG performance status (PS) 0, 1 or 2

  • ARM D: Patients must meet at least 1 of these 3 laboratory criteria to be enrolled:

    • Hemoglobin =< 10g/dL (obtained =< 7 days prior to registration)
    • Absolute neutrophil count (ANC) =< 1000/mm^3 (obtained =< 7 days prior to registration)
    • Platelet count =< 100,000/mm^ 3 (obtained =< 7 days prior to registration)
  • ARM D: Total bilirubin =< 2 x ULN (if > 2 x ULN direct bilirubin is required and should be =< 1.5 x ULN) (obtained =<7 days prior to registration)

  • ARM D: Alanine aminotransferase (ALT) and aspartate transaminase (AST) =< 3 x ULN (=< 5 x ULN for patients with liver involvement) (obtained =<7 days prior to registration)

  • ARM D: Creatinine =< 1.6 mg/dL (obtained =<7 days prior to registration). If > 1.6, then the Calculated creatinine clearance must be >= 55 ml/min using the Cockcroft-Gault formula

  • ARM D: Negative pregnancy test, for persons of childbearing potential only (obtained =< 7 days prior to registration). NOTE: If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.

  • ARM D: Provide written informed consent

  • ARM D: Willingness to have a central venous line (PICC or PORT)

  • ARM D: Willingness to provide mandatory blood specimens for correlative research

  • ARM D: Willingness to return to enrolling institution (MCR) for follow-up (during the active monitoring phase of the study)

  • ARM D: Willingness to follow the requirements of the intravenous ascorbic acid program schedule

  • ARM E PRE-REGISTRATION: Age ≥ 18 years

  • ARM E PRE-REGISTRATION: New or an established diagnosis of 2016 World Health Organization (WHO) defined chronic myelomonocytic leukemia with a somatic TET2, IDH1, or IDH2 mutation requiring treatment with DNA methyltransferase inhibitors/hypomethylating agents

  • ARM E PRE-REGISTRATION: No prior CMML directed therapy.

    • Exception: Received ≤ 1 cycle of azacitidine, decitabine, erythropoiesis stimulating agent therapy (ESA), or oral decitabine and cedazuridine. NOTE: Prior exposure to hydroxyurea is allowed. Continuation beyond the first cycle must be discussed with the principal investigator (PI)
  • ARM E PRE-REGISTRATION: Willingness to provide mandatory research bone marrow sample for correlative research

  • ARM E PRE-REGISTRATION: ECOG performance status (PS) 0, 1, or 2

  • ARM E PRE-REGISTRATION: Provide written informed consent

  • ARM E PRE-REGISTRATION: Platelet count ≥ 20,000/mm^3 (obtained ≤ 14 days prior to pre-registration)

  • ARM E PRE-REGISTRATION: Total bilirubin ≤ 1.5 x ULN ( ≤ 3 x ULN for patients with Gilbert's syndrome) (obtained ≤ 14 days prior to pre-registration)

  • ARM E PRE-REGISTRATION: Alanine aminotransferase (ALT) and aspartate transaminase (AST) ≤ 3 x ULN (obtained ≤ 14 days prior to pre-registration)

  • ARM E PRE-REGISTRATION: Creatinine ≤ 1.6 mg/dL. If > 1.6, then the Calculated creatinine clearance must be ≥ 55 ml/min using the Cockcroft-Gault formula

  • ARM E PRE-REGISTRATION: For a person of child-bearing potential (WOCBP): Must agree to use contraception or take measures to avoid pregnancy during the study. Adequate contraception is defined as follows:

    • Complete true abstinence

    • Consistent and correct use of one of the following methods of birth control:

      • Male partner who is sterile prior to the female patient's entry into the study and is the sole sexual partner for that female patient
      • Implants of levonorgestrel
      • Injectable progestogen
      • Intrauterine device (IUD) with a documented failure rate of less than 1% per year
      • Oral contraceptive pill (either combined or progesterone only)
      • Barrier method, for example: diaphragm with spermicide or condom with spermicide in combination with either implants of levonorgestrel or injectable progestogen
  • ARM E PRE-REGISTRATION: WOCBP must have a negative serum or urine pregnancy test ≤ 14 days prior to pre-registration. WOCBP will repeat the serum or urine pregnancy test ≤ 7 days prior to the initiation of starting treatment for confirmation of a negative pregnancy.

    • NOTE: WOCBP include any person who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is not postmenopausal (defined as amenorrhea > 12 consecutive months); or women on hormone replacement therapy with documented serum follicle stimulating hormone (FSH) level > 35 mIU/mL. Even women who are using oral, implanted, or injectable contraceptive hormones or mechanical products such as an IUD or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy or practicing abstinence or where partner is sterile (e.g., vasectomy), must be considered to be of child-bearing potential. NOTE: If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
  • ARM E PRE-REGISTRATION: Persons who are able to father a child must use contraception during the study and for 3 months after the last treatment dose.

    • Complete true abstinence
    • Latex condom with a spermicidal agent
    • Diaphragm with spermicide
  • ARM E REGISTRATION: Willingness to provide mandatory blood specimens for correlative research

  • ARM E REGISTRATION: Willingness to return to enrolling institution (MCR) for follow-up (during the active monitoring phase of the study)

  • ARM E REGISTRATION: Recovered to grade 1 or baseline or established as sequelae from all toxic effects of previous therapy except alopecia

  • ARM E REGISTRATION: Ability to complete questionnaire by themselves or with assistance

  • ARM E REGISTRATION: Willingness to have a central venous line (PICC or PORT)

  • ARM E REGISTRATION: Willingness to follow the requirements of the intravenous ascorbic acid program schedule

Exclusion Criteria:

  • Any of the following:

    • Pregnant persons
    • Nursing persons
    • Persons of childbearing potential who are unwilling to employ adequate contraception
  • Any therapy =< 2 weeks prior to registration; NOTE: Exception: patients on ibrutinib or corticosteroids (any dose) may continue therapy up until the new regimen has started at investigator discretion; corticosteroids can be tapered to lowest possible dose after start of treatment at investigator discretion. Exception: Palliative radiation is allowed

  • Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens

  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, pulmonary congestion or pulmonary edema, clinical dehydration, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

  • Receiving any other investigational agent which would be considered as a treatment for the lymphoma

  • Other active malignancy than lymphoma

    • NOTE: If there is a history of prior malignancy, they must not be receiving other specific treatment for their cancer that could interfere with this protocol therapy; patients on hormonal therapy for treated breast or prostate cancer are permitted if they meet other eligibility criteria; patients with non-melanotic skin cancer may enroll
  • History of myocardial infarction =< 6 months, or current symptomatic congestive heart failure or left ventricular ejection fraction (LVEF) < 40% or with > grade 2 diastolic dysfunction, with no symptoms or signs of heart failure

  • Known G6PD (glucose-6-phosphate dehydrogenase) deficiency (below lower limit of normal)

  • Patients with active central nervous system (CNS) lymphoma or active cerebrospinal fluid (CSF) involvement with malignant cells requiring CNS-specific therapy with IV or intrathecal (IT) methotrexate (MTX); Note: Patients with any prior CNS lymphoma (parenchymal or leptomeningeal) MUST be in complete remission (CR) in those compartments without any maintenance therapy required

  • Patients with uncontrolled or symptomatic kidney stones

  • Known paroxysmal nocturnal hemoglobinuria (PNH)

  • ARM D: Bona-fide hematological neoplasm

  • ARM D: Any of the following because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects:

    • Pregnant persons
    • Nursing persons
    • Persons of childbearing potential who are unwilling to employ adequate contraception
  • ARM D: Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens

  • ARM D: Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, pulmonary congestion or pulmonary edema, clinical dehydration, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

  • ARM D: History of myocardial infarction =< 6 months, or current symptomatic congestive heart failure or known LVEF < 40% or with > grade 2 diastolic dysfunction, with no symptoms or signs of heart failure

  • ARM D: Patients with uncontrolled or symptomatic kidney stones

  • ARM D: Known paroxysmal nocturnal hemoglobinuria (PNH)

  • ARM D: Known G6PD (glucose-6-phosphate dehydrogenase) deficiency (below lower limit of normal)

  • ARM E PRE-REGISTRATION: Myelodysplastic syndrome (MDS)/myeloproliferative neoplasm (MPN) overlap syndromes other than CMML

  • ARM E PRE-REGISTRATION: Active central nervous system disease

  • ARM E PRE-REGISTRATION: Any active disease condition that would render the protocol treatment dangerous or impair the ability of the patient to receive study drug

  • ARM E PRE-REGISTRATION: Concurrent active malignancy, except adequately treated nonmelanoma skin cancer. History of curatively treated in situ cancer of the cervix, curatively treated in situ cancer of the breast, or other solid tumors curatively treated is allowed as long as there is no evidence of disease for > 2 years

  • ARM E PRE-REGISTRATION: Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens

  • ARM E PRE-REGISTRATION: Disease requiring systemic treatment with systemic immunosuppression with steroid steroids at a dose of ≥ 20 mg/day prednisone (or equivalent). Exceptions: Intermittent use of bronchodilators or inhaled steroids, local steroid injections, topical steroids

  • ARM E PRE-REGISTRATION: Patients with uncontrolled or symptomatic kidney stones

  • ARM E REGISTRATION: New York Heart Association (NYHA) class III/IV heart failure or active angina/angina equivalents

  • ARM E REGISTRATION: History of myocardial infarction ≤ 6 months, or current symptomatic congestive heart failure or known LVEF < 40% or with > grade 2 diastolic dysfunction, with no symptoms or signs of heart failure

  • ARM E REGISTRATION: Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, clinically significant cardiac arrhythmia, unstable angina pectoris, clinically significant nonhealing or healing wounds, pulmonary congestion or pulmonary edema, significant pulmonary disease (shortness of breath at rest or mild exertion), uncontrolled infection, clinical dehydration, or psychiatric illness/social situations that would limit compliance with study requirements

  • ARM E REGISTRATION: Known G6PD (glucose-6-phosphate dehydrogenase) deficiency (below lower limit of normal)

  • ARM E REGISTRATION: Any of the following because this study involves an agent that has known genotoxic, mutagenic, and teratogenic effects:

    • Pregnant persons
    • Nursing persons
    • Persons of childbearing potential who are unwilling to employ adequate contraception

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 더블

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Arm A (ascorbic acid, combination chemotherapy) - closed to enrollment

Patients receive ascorbic acid IV on days 1, 3, 5, 8, 10, 12, 15, 17, and 19, and rituximab intravenously IV, ifosfamide IV, carboplatin IV and etoposide IV on days 1-3. Patients who achieve MR or SD after 2 cycles may receive rituximab IV or PO, cisplatin IV or PO, cytarabine IV or PO, and dexamethasone IV or PO. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients additionally, undergo blood sample collection, core needle biopsy, bone marrow aspiration and biopsy, ECHO, PET/CT or MRI throughout study.

Correlative studies

Undergo blood sample collection

다른 이름들:
  • 생물학적 샘플 수집
  • 생체 표본 수집
  • 표본 수집

Given IV or PO

다른 이름들:
  • 데카드론
  • 헤마디
  • Aacidexam
  • 아덱손
  • 아크니히톨 덱사
  • 알바덱스
  • 알린
  • 알린 디포
  • 알린 오프탈미코
  • 증폭
  • 안물모노
  • 오리쿨라룸
  • 옥실로손
  • 베이카드론
  • 바이큐텐
  • 베이큐튼 N
  • 코르티덱사손
  • 코르티섬만
  • 데카코트
  • 데카드롤
  • 데카드론 DP
  • 데칼릭스
  • 데카메스
  • 데카손 R.p.
  • 데탄실
  • 델타플루오렌
  • 데로닐
  • 데사메타손
  • 데사메톤
  • 덱사-마말렛
  • 덱사-코뿔소
  • 덱사-스케로손
  • 덱사 사인
  • 덱사피질
  • 덱사코르틴
  • 덱사파마
  • 덱사플루오렌
  • 덱사로컬
  • 덱사메코르틴
  • 덱사메스
  • 덱사메타손 인텐솔
  • 덱사메타소눔
  • 덱사모노존
  • 덱사포스
  • 덱시노랄
  • 덱손
  • 다이노르몬
  • 드제보
  • 플루오로델타
  • 포르테코틴
  • 감마코르텐
  • 헥사데카드롤
  • 헥사드롤
  • 로컬리슨-F
  • 로베린
  • 메틸플루오르프레드니솔론
  • 밀리코트
  • 마이메타손
  • 오르가드론
  • 스퍼사덱스
  • 테이퍼덱스
  • 비스메타존
  • 조덱스

Given IV

다른 이름들:
  • 리툭산
  • 맙테라
  • ABP 798
  • BI 695500
  • C2B8 단클론항체
  • 키메라 항-CD20 항체
  • CT-P10
  • IDEC-102
  • IDEC-C2B8
  • IDEC-C2B8 단클론항체
  • 단클론항체 IDEC-C2B8
  • PF-05280586
  • 리아브니
  • 리툭시맙 ABBS
  • 리툭시맙 ARRX
  • 리툭시맙 바이오시밀러 ABP 798
  • 리툭시맙 바이오시밀러 BI 695500
  • 리툭시맙 바이오시밀러 CT-P10
  • 리툭시맙 바이오시밀러 GB241
  • 리툭시맙 바이오시밀러 IBI301
  • 리툭시맙 바이오시밀러 JHL1101
  • 리툭시맙 바이오시밀러 PF-05280586
  • 리툭시맙 바이오시밀러 RTXM83
  • 리툭시맙 바이오시밀러 SAIT101
  • 리툭시맙 바이오시밀러 SIBP-02
  • 리툭시맙 바이오시밀러 TQB2303
  • 리툭시맙 PVVR
  • 리툭시맙-arrx
  • 리툭시맙-pvvr
  • RTXM83
  • 루시언스
  • 트룩시마
  • 익다르
  • 맘타스
  • 리툭시맙-abbs

Undergo MRI

다른 이름들:
  • MRI
  • 자기 공명
  • 자기공명영상 스캔
  • 씨
  • MR 이미징
  • MRI 검사
  • NMR 이미징
  • NMRI
  • 의료 영상
  • 자기공명 / 핵자기공명
  • 핵 자기 공명 영상
  • 자기공명영상(MRI)
  • SMRI
  • 자기공명영상(시술)
  • 구조적 MRI

Ancillary studies

Undergo bone marrow aspiration and biopsy

Undergo bone marrow aspiration and biopsy

다른 이름들:
  • 골수 생검
  • 생검, 골수

Undergo PET/CT

다른 이름들:
  • 의료 영상, 양전자 방출 단층 촬영
  • 애완 동물
  • PET 스캔
  • 양전자 방출 단층 촬영
  • 양성자 자기 공명 분광 이미징
  • PT
  • 양전자 방출 단층 촬영 스캔
  • 양전자방출단층촬영(시술)

Given IV

다른 이름들:
  • 비타민 C
  • 2-(1,2-디히드록시에틸)-4,5-디히드록시-푸란-3-온
  • 아소비캡
  • C 비타민
  • C-롱
  • 세비솔
  • 세콘
  • 세놀레이트
  • 세탄
  • 세발린
  • L-아스코르빈산
  • VIT C

Given IV or PO

다른 이름들:
  • 폭발탄
  • 카르보플라트
  • 카보플라틴 헥살
  • 카르보플라티노
  • 카보플라티넘
  • 카르보신
  • 카보솔
  • 카보텍
  • CBDCA
  • 디스플라타
  • 에르카르
  • JM-8
  • 닐로린
  • 노보플라티넘
  • 파라플라틴
  • 파라플라틴 AQ
  • 플라틴와스
  • 리보카르보
  • JM8

Given IV or PO

다른 이름들:
  • CDDP
  • 시스-디암민디클로리도백금
  • 시스마플라트
  • 시스플라티넘
  • 네오플라틴
  • 플라티놀
  • 아비플라틴
  • 블라스톨렘
  • 브리플라틴
  • 시스-디아민-디클로로백금
  • 시스-디아민디클로로 백금(II)
  • 시스-디아민디클로로백금
  • 시스-디클로로암민 백금(II)
  • 시스-백금 디아민 디클로라이드
  • 시스-백금
  • 시스-백금 II
  • 시스-백금 II 디아민 디클로라이드
  • 시스플라티나
  • 시스플라틸
  • 치토플라티노
  • 시토신
  • DDP
  • 레더플라틴
  • 메타플라틴
  • Peyrone의 염화물
  • 페이론의 소금
  • 플라시스
  • 플라스티스틸
  • 플라타민
  • 플라티블라스틴
  • 플라티블라스틴-S
  • 플래티넥스
  • 플라티놀-AQ
  • 플라티놀-AQ VHA 플러스
  • 플라티녹산
  • 백금
  • 백금 디암미노디클로라이드
  • 플라티란
  • 플라티스틴
  • 플라토신

Given IV or PO

다른 이름들:
  • .베타.-시토신 아라비노사이드
  • 1-.베타.-D-아라비노푸라노실-4-아미노-2(1H)피리미디논
  • 1-.beta.-D-Arabinofuranosylcytosine
  • 1-베타-D-아라비노푸라노실-4-아미노-2(1H)피리미디논
  • 1-베타-D-아라비노푸라노실시토신
  • 1.베타.-D-아라비노푸라노실시토신
  • 2(1H)-피리미디논, 4-아미노-1-베타-D-아라비노푸라노실-
  • 2(1H)-피리미디논, 4-아미노-1.베타.-D-아라비노푸라노실-
  • 알렉산
  • 아라씨
  • ARA 세포
  • 아라빈
  • 아라비노푸라노실시토신
  • 아라비노실시토신
  • 아라시티딘
  • 아라시티틴
  • 베타-시토신 아라비노사이드
  • CHX-3311
  • 시타라비눔
  • 시타벨
  • 사이토사르
  • 시토신 아라비노사이드
  • 시토신-.베타.-아라비노사이드
  • 시토신-베타-아라비노사이드
  • 에르팔파
  • 스타라시드
  • 타라빈 PFS
  • 유 19920
  • U-19920
  • 우디실
  • WR-28453

Given IV or PO

다른 이름들:
  • 데메틸 에피포도필로톡신 에틸리딘 글루코사이드
  • 에펙
  • 라셋
  • 토포사르
  • 베페시드
  • 부사장 16
  • 부사장 16-213
  • VP-16
  • VP-16-213
  • VP16
  • VP 16213

Given IV or PO

다른 이름들:
  • 아스타 Z 4942
  • 아스타 Z-4942
  • 싸이포스
  • 홀로산
  • 홀로세인
  • 아이펙스
  • IFO
  • IFO-셀
  • 이폴렘
  • 이포미다
  • 이포마이드
  • 이포스파미둠
  • 이폭산
  • IFX
  • 이포스파미드
  • 이포스파마이드
  • 이소엔독산
  • 이소포스파마이드
  • 미톡사나
  • 엠제이프 9325
  • MJF-9325
  • 낙사마이드
  • 세로미다
  • 트로녹살
  • Z 4942
  • Z-4942

Undergo core needle biopsy

다른 이름들:
  • 생검, 핵심
  • 코어 니들
  • 핵심 바늘 생검
  • 바늘 생검
  • 코어 CNB

Undergo ECHO

다른 이름들:
  • EC
  • 에코

Undergo PET/CT

다른 이름들:
  • CT
  • 고양이
  • 고양이 스캔
  • 컴퓨터 축 단층 촬영
  • 전산화 단층 촬영
  • 단층 촬영
  • CT 스캔
  • 컴퓨터 축 단층 촬영(시술)
  • 컴퓨터 단층촬영(CT) 스캔
활성 비교기: Arm B (placebo, combination chemotherapy) - closed to enrollment

Patients receive placebo (normal saline) IV on days 1, 3, 5, 8, 10, 12, 15, 17, and 19, and rituximab intravenously IV, ifosfamide IV, carboplatin IV and etoposide IV on days 1-3. Patients who achieve MR or SD after 2 cycles may receive rituximab IV or PO, cisplatin IV or PO, cytarabine IV or PO, and dexamethasone IV or PO. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients additionally, undergo blood sample collection, core needle biopsy, bone marrow aspiration and biopsy, ECHO, PET/CT or MRI throughout study.

Correlative studies

Undergo blood sample collection

다른 이름들:
  • 생물학적 샘플 수집
  • 생체 표본 수집
  • 표본 수집

Given IV or PO

다른 이름들:
  • 데카드론
  • 헤마디
  • Aacidexam
  • 아덱손
  • 아크니히톨 덱사
  • 알바덱스
  • 알린
  • 알린 디포
  • 알린 오프탈미코
  • 증폭
  • 안물모노
  • 오리쿨라룸
  • 옥실로손
  • 베이카드론
  • 바이큐텐
  • 베이큐튼 N
  • 코르티덱사손
  • 코르티섬만
  • 데카코트
  • 데카드롤
  • 데카드론 DP
  • 데칼릭스
  • 데카메스
  • 데카손 R.p.
  • 데탄실
  • 델타플루오렌
  • 데로닐
  • 데사메타손
  • 데사메톤
  • 덱사-마말렛
  • 덱사-코뿔소
  • 덱사-스케로손
  • 덱사 사인
  • 덱사피질
  • 덱사코르틴
  • 덱사파마
  • 덱사플루오렌
  • 덱사로컬
  • 덱사메코르틴
  • 덱사메스
  • 덱사메타손 인텐솔
  • 덱사메타소눔
  • 덱사모노존
  • 덱사포스
  • 덱시노랄
  • 덱손
  • 다이노르몬
  • 드제보
  • 플루오로델타
  • 포르테코틴
  • 감마코르텐
  • 헥사데카드롤
  • 헥사드롤
  • 로컬리슨-F
  • 로베린
  • 메틸플루오르프레드니솔론
  • 밀리코트
  • 마이메타손
  • 오르가드론
  • 스퍼사덱스
  • 테이퍼덱스
  • 비스메타존
  • 조덱스

Given IV

다른 이름들:
  • 리툭산
  • 맙테라
  • ABP 798
  • BI 695500
  • C2B8 단클론항체
  • 키메라 항-CD20 항체
  • CT-P10
  • IDEC-102
  • IDEC-C2B8
  • IDEC-C2B8 단클론항체
  • 단클론항체 IDEC-C2B8
  • PF-05280586
  • 리아브니
  • 리툭시맙 ABBS
  • 리툭시맙 ARRX
  • 리툭시맙 바이오시밀러 ABP 798
  • 리툭시맙 바이오시밀러 BI 695500
  • 리툭시맙 바이오시밀러 CT-P10
  • 리툭시맙 바이오시밀러 GB241
  • 리툭시맙 바이오시밀러 IBI301
  • 리툭시맙 바이오시밀러 JHL1101
  • 리툭시맙 바이오시밀러 PF-05280586
  • 리툭시맙 바이오시밀러 RTXM83
  • 리툭시맙 바이오시밀러 SAIT101
  • 리툭시맙 바이오시밀러 SIBP-02
  • 리툭시맙 바이오시밀러 TQB2303
  • 리툭시맙 PVVR
  • 리툭시맙-arrx
  • 리툭시맙-pvvr
  • RTXM83
  • 루시언스
  • 트룩시마
  • 익다르
  • 맘타스
  • 리툭시맙-abbs

Undergo MRI

다른 이름들:
  • MRI
  • 자기 공명
  • 자기공명영상 스캔
  • 씨
  • MR 이미징
  • MRI 검사
  • NMR 이미징
  • NMRI
  • 의료 영상
  • 자기공명 / 핵자기공명
  • 핵 자기 공명 영상
  • 자기공명영상(MRI)
  • SMRI
  • 자기공명영상(시술)
  • 구조적 MRI

Ancillary studies

Undergo bone marrow aspiration and biopsy

Undergo bone marrow aspiration and biopsy

다른 이름들:
  • 골수 생검
  • 생검, 골수

Undergo PET/CT

다른 이름들:
  • 의료 영상, 양전자 방출 단층 촬영
  • 애완 동물
  • PET 스캔
  • 양전자 방출 단층 촬영
  • 양성자 자기 공명 분광 이미징
  • PT
  • 양전자 방출 단층 촬영 스캔
  • 양전자방출단층촬영(시술)

Given IV or PO

다른 이름들:
  • 폭발탄
  • 카르보플라트
  • 카보플라틴 헥살
  • 카르보플라티노
  • 카보플라티넘
  • 카르보신
  • 카보솔
  • 카보텍
  • CBDCA
  • 디스플라타
  • 에르카르
  • JM-8
  • 닐로린
  • 노보플라티넘
  • 파라플라틴
  • 파라플라틴 AQ
  • 플라틴와스
  • 리보카르보
  • JM8

Given IV or PO

다른 이름들:
  • CDDP
  • 시스-디암민디클로리도백금
  • 시스마플라트
  • 시스플라티넘
  • 네오플라틴
  • 플라티놀
  • 아비플라틴
  • 블라스톨렘
  • 브리플라틴
  • 시스-디아민-디클로로백금
  • 시스-디아민디클로로 백금(II)
  • 시스-디아민디클로로백금
  • 시스-디클로로암민 백금(II)
  • 시스-백금 디아민 디클로라이드
  • 시스-백금
  • 시스-백금 II
  • 시스-백금 II 디아민 디클로라이드
  • 시스플라티나
  • 시스플라틸
  • 치토플라티노
  • 시토신
  • DDP
  • 레더플라틴
  • 메타플라틴
  • Peyrone의 염화물
  • 페이론의 소금
  • 플라시스
  • 플라스티스틸
  • 플라타민
  • 플라티블라스틴
  • 플라티블라스틴-S
  • 플래티넥스
  • 플라티놀-AQ
  • 플라티놀-AQ VHA 플러스
  • 플라티녹산
  • 백금
  • 백금 디암미노디클로라이드
  • 플라티란
  • 플라티스틴
  • 플라토신

Given IV or PO

다른 이름들:
  • .베타.-시토신 아라비노사이드
  • 1-.베타.-D-아라비노푸라노실-4-아미노-2(1H)피리미디논
  • 1-.beta.-D-Arabinofuranosylcytosine
  • 1-베타-D-아라비노푸라노실-4-아미노-2(1H)피리미디논
  • 1-베타-D-아라비노푸라노실시토신
  • 1.베타.-D-아라비노푸라노실시토신
  • 2(1H)-피리미디논, 4-아미노-1-베타-D-아라비노푸라노실-
  • 2(1H)-피리미디논, 4-아미노-1.베타.-D-아라비노푸라노실-
  • 알렉산
  • 아라씨
  • ARA 세포
  • 아라빈
  • 아라비노푸라노실시토신
  • 아라비노실시토신
  • 아라시티딘
  • 아라시티틴
  • 베타-시토신 아라비노사이드
  • CHX-3311
  • 시타라비눔
  • 시타벨
  • 사이토사르
  • 시토신 아라비노사이드
  • 시토신-.베타.-아라비노사이드
  • 시토신-베타-아라비노사이드
  • 에르팔파
  • 스타라시드
  • 타라빈 PFS
  • 유 19920
  • U-19920
  • 우디실
  • WR-28453

Given IV or PO

다른 이름들:
  • 데메틸 에피포도필로톡신 에틸리딘 글루코사이드
  • 에펙
  • 라셋
  • 토포사르
  • 베페시드
  • 부사장 16
  • 부사장 16-213
  • VP-16
  • VP-16-213
  • VP16
  • VP 16213

Given IV or PO

다른 이름들:
  • 아스타 Z 4942
  • 아스타 Z-4942
  • 싸이포스
  • 홀로산
  • 홀로세인
  • 아이펙스
  • IFO
  • IFO-셀
  • 이폴렘
  • 이포미다
  • 이포마이드
  • 이포스파미둠
  • 이폭산
  • IFX
  • 이포스파미드
  • 이포스파마이드
  • 이소엔독산
  • 이소포스파마이드
  • 미톡사나
  • 엠제이프 9325
  • MJF-9325
  • 낙사마이드
  • 세로미다
  • 트로녹살
  • Z 4942
  • Z-4942

Undergo core needle biopsy

다른 이름들:
  • 생검, 핵심
  • 코어 니들
  • 핵심 바늘 생검
  • 바늘 생검
  • 코어 CNB

Undergo ECHO

다른 이름들:
  • EC
  • 에코

Undergo PET/CT

다른 이름들:
  • CT
  • 고양이
  • 고양이 스캔
  • 컴퓨터 축 단층 촬영
  • 전산화 단층 촬영
  • 단층 촬영
  • CT 스캔
  • 컴퓨터 축 단층 촬영(시술)
  • 컴퓨터 단층촬영(CT) 스캔

Given normal saline IV

실험적: Arm C (ascorbic acid and combination chemotherapy) - closed to enrollment

Patients receive ascorbic acid IV on days 1, 3, 5, 8, 10, 12, 15, 17, and 19. Patients also receive ifosfamide, carboplatin, and etoposide IV or PO, or cisplatin, cytarabine, and dexamethasone IV or PO, or gemcitabine hydrochloride, dexamethasone, and cisplatin IV or PO, or gemcitabine hydrochloride and oxaliplatin IV or PO, or oxaliplatin, cytarabine, and dexamethasone IV or PO according to standard regimen schedule. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve MR or SD after 2 cycles may switch to an alternative chemotherapy regimen. Patients additionally, undergo blood sample collection, core needle biopsy, bone marrow aspiration and biopsy, ECHO, PET/CT or MRI throughout study.

Correlative studies

Undergo blood sample collection

다른 이름들:
  • 생물학적 샘플 수집
  • 생체 표본 수집
  • 표본 수집

Given IV or PO

다른 이름들:
  • 데카드론
  • 헤마디
  • Aacidexam
  • 아덱손
  • 아크니히톨 덱사
  • 알바덱스
  • 알린
  • 알린 디포
  • 알린 오프탈미코
  • 증폭
  • 안물모노
  • 오리쿨라룸
  • 옥실로손
  • 베이카드론
  • 바이큐텐
  • 베이큐튼 N
  • 코르티덱사손
  • 코르티섬만
  • 데카코트
  • 데카드롤
  • 데카드론 DP
  • 데칼릭스
  • 데카메스
  • 데카손 R.p.
  • 데탄실
  • 델타플루오렌
  • 데로닐
  • 데사메타손
  • 데사메톤
  • 덱사-마말렛
  • 덱사-코뿔소
  • 덱사-스케로손
  • 덱사 사인
  • 덱사피질
  • 덱사코르틴
  • 덱사파마
  • 덱사플루오렌
  • 덱사로컬
  • 덱사메코르틴
  • 덱사메스
  • 덱사메타손 인텐솔
  • 덱사메타소눔
  • 덱사모노존
  • 덱사포스
  • 덱시노랄
  • 덱손
  • 다이노르몬
  • 드제보
  • 플루오로델타
  • 포르테코틴
  • 감마코르텐
  • 헥사데카드롤
  • 헥사드롤
  • 로컬리슨-F
  • 로베린
  • 메틸플루오르프레드니솔론
  • 밀리코트
  • 마이메타손
  • 오르가드론
  • 스퍼사덱스
  • 테이퍼덱스
  • 비스메타존
  • 조덱스

Undergo MRI

다른 이름들:
  • MRI
  • 자기 공명
  • 자기공명영상 스캔
  • 씨
  • MR 이미징
  • MRI 검사
  • NMR 이미징
  • NMRI
  • 의료 영상
  • 자기공명 / 핵자기공명
  • 핵 자기 공명 영상
  • 자기공명영상(MRI)
  • SMRI
  • 자기공명영상(시술)
  • 구조적 MRI

Ancillary studies

Undergo bone marrow aspiration and biopsy

Undergo bone marrow aspiration and biopsy

다른 이름들:
  • 골수 생검
  • 생검, 골수

Undergo PET/CT

다른 이름들:
  • 의료 영상, 양전자 방출 단층 촬영
  • 애완 동물
  • PET 스캔
  • 양전자 방출 단층 촬영
  • 양성자 자기 공명 분광 이미징
  • PT
  • 양전자 방출 단층 촬영 스캔
  • 양전자방출단층촬영(시술)

Given IV

다른 이름들:
  • 비타민 C
  • 2-(1,2-디히드록시에틸)-4,5-디히드록시-푸란-3-온
  • 아소비캡
  • C 비타민
  • C-롱
  • 세비솔
  • 세콘
  • 세놀레이트
  • 세탄
  • 세발린
  • L-아스코르빈산
  • VIT C

Given IV or PO

다른 이름들:
  • 폭발탄
  • 카르보플라트
  • 카보플라틴 헥살
  • 카르보플라티노
  • 카보플라티넘
  • 카르보신
  • 카보솔
  • 카보텍
  • CBDCA
  • 디스플라타
  • 에르카르
  • JM-8
  • 닐로린
  • 노보플라티넘
  • 파라플라틴
  • 파라플라틴 AQ
  • 플라틴와스
  • 리보카르보
  • JM8

Given IV or PO

다른 이름들:
  • CDDP
  • 시스-디암민디클로리도백금
  • 시스마플라트
  • 시스플라티넘
  • 네오플라틴
  • 플라티놀
  • 아비플라틴
  • 블라스톨렘
  • 브리플라틴
  • 시스-디아민-디클로로백금
  • 시스-디아민디클로로 백금(II)
  • 시스-디아민디클로로백금
  • 시스-디클로로암민 백금(II)
  • 시스-백금 디아민 디클로라이드
  • 시스-백금
  • 시스-백금 II
  • 시스-백금 II 디아민 디클로라이드
  • 시스플라티나
  • 시스플라틸
  • 치토플라티노
  • 시토신
  • DDP
  • 레더플라틴
  • 메타플라틴
  • Peyrone의 염화물
  • 페이론의 소금
  • 플라시스
  • 플라스티스틸
  • 플라타민
  • 플라티블라스틴
  • 플라티블라스틴-S
  • 플래티넥스
  • 플라티놀-AQ
  • 플라티놀-AQ VHA 플러스
  • 플라티녹산
  • 백금
  • 백금 디암미노디클로라이드
  • 플라티란
  • 플라티스틴
  • 플라토신

Given IV or PO

다른 이름들:
  • .베타.-시토신 아라비노사이드
  • 1-.베타.-D-아라비노푸라노실-4-아미노-2(1H)피리미디논
  • 1-.beta.-D-Arabinofuranosylcytosine
  • 1-베타-D-아라비노푸라노실-4-아미노-2(1H)피리미디논
  • 1-베타-D-아라비노푸라노실시토신
  • 1.베타.-D-아라비노푸라노실시토신
  • 2(1H)-피리미디논, 4-아미노-1-베타-D-아라비노푸라노실-
  • 2(1H)-피리미디논, 4-아미노-1.베타.-D-아라비노푸라노실-
  • 알렉산
  • 아라씨
  • ARA 세포
  • 아라빈
  • 아라비노푸라노실시토신
  • 아라비노실시토신
  • 아라시티딘
  • 아라시티틴
  • 베타-시토신 아라비노사이드
  • CHX-3311
  • 시타라비눔
  • 시타벨
  • 사이토사르
  • 시토신 아라비노사이드
  • 시토신-.베타.-아라비노사이드
  • 시토신-베타-아라비노사이드
  • 에르팔파
  • 스타라시드
  • 타라빈 PFS
  • 유 19920
  • U-19920
  • 우디실
  • WR-28453

Given IV or PO

다른 이름들:
  • 데메틸 에피포도필로톡신 에틸리딘 글루코사이드
  • 에펙
  • 라셋
  • 토포사르
  • 베페시드
  • 부사장 16
  • 부사장 16-213
  • VP-16
  • VP-16-213
  • VP16
  • VP 16213

Given IV or PO

다른 이름들:
  • 아스타 Z 4942
  • 아스타 Z-4942
  • 싸이포스
  • 홀로산
  • 홀로세인
  • 아이펙스
  • IFO
  • IFO-셀
  • 이폴렘
  • 이포미다
  • 이포마이드
  • 이포스파미둠
  • 이폭산
  • IFX
  • 이포스파미드
  • 이포스파마이드
  • 이소엔독산
  • 이소포스파마이드
  • 미톡사나
  • 엠제이프 9325
  • MJF-9325
  • 낙사마이드
  • 세로미다
  • 트로녹살
  • Z 4942
  • Z-4942

Undergo core needle biopsy

다른 이름들:
  • 생검, 핵심
  • 코어 니들
  • 핵심 바늘 생검
  • 바늘 생검
  • 코어 CNB

Undergo ECHO

다른 이름들:
  • EC
  • 에코

Undergo PET/CT

다른 이름들:
  • CT
  • 고양이
  • 고양이 스캔
  • 컴퓨터 축 단층 촬영
  • 전산화 단층 촬영
  • 단층 촬영
  • CT 스캔
  • 컴퓨터 축 단층 촬영(시술)
  • 컴퓨터 단층촬영(CT) 스캔

Given IV or PO

다른 이름들:
  • 젬자
  • dFdCyd
  • 디플루오로데옥시시티딘 염산염
  • 젬시타빈 HCI
  • LY-188011
  • LY188011

Given IV or PO

다른 이름들:
  • 1-OHP
  • 다코틴
  • 닥플라
  • 엘록사틴
  • 아이 헹
  • 아이헝
  • 디아미노시클로헥산 옥살라토백금
  • JM-83
  • 옥살라토플라틴
  • 옥살라토백금
  • RP 54780
  • RP-54780
  • SR-96669
실험적: Arm D (ascorbic acid) - closed to enrollment

Patients receive ascorbic acid IV TIW. Treatments repeat every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo PICC or portacath placement prior to starting treatment, blood sample collection, bone marrow aspiration and biopsy throughout study.

Correlative studies

Undergo blood sample collection

다른 이름들:
  • 생물학적 샘플 수집
  • 생체 표본 수집
  • 표본 수집

Ancillary studies

Undergo bone marrow aspiration and biopsy

Undergo bone marrow aspiration and biopsy

다른 이름들:
  • 골수 생검
  • 생검, 골수

Given IV

다른 이름들:
  • 비타민 C
  • 2-(1,2-디히드록시에틸)-4,5-디히드록시-푸란-3-온
  • 아소비캡
  • C 비타민
  • C-롱
  • 세비솔
  • 세콘
  • 세놀레이트
  • 세탄
  • 세발린
  • L-아스코르빈산
  • VIT C

Undergo PICC placement

다른 이름들:
  • 중심정맥 카테터
  • 중심 정맥 카테터 배치

Undergo portacath placement

다른 이름들:
  • 휴대용 카트 배치
실험적: ARM E (ascorbic acid, decitabine)

Patients receive ascorbic acid IV on days 1, 3 and 5 and decitabine IV over 1 hour on days 1-5. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients with stable disease after 12 cycles may continue decitabine with or without ascorbic acid as long as clinically appropriate. Patients may also take vitamin C PO on days 6-28. Patients undergo PICC or portacath placement prior to starting treatment, blood sample collection, bone marrow aspiration and biopsy throughout study.

Given IV

다른 이름들:
  • 다코젠
  • 주사용 데시타빈
  • 데옥시아자시티딘
  • 데조시티딘

Undergo blood sample collection

다른 이름들:
  • 생물학적 샘플 수집
  • 생체 표본 수집
  • 표본 수집

Undergo bone marrow aspiration and biopsy

Undergo bone marrow aspiration and biopsy

다른 이름들:
  • 골수 생검
  • 생검, 골수

Given IV

다른 이름들:
  • 비타민 C
  • 2-(1,2-디히드록시에틸)-4,5-디히드록시-푸란-3-온
  • 아소비캡
  • C 비타민
  • C-롱
  • 세비솔
  • 세콘
  • 세놀레이트
  • 세탄
  • 세발린
  • L-아스코르빈산
  • VIT C

Undergo PICC placement

다른 이름들:
  • 중심정맥 카테터
  • 중심 정맥 카테터 배치

Undergo portacath placement

다른 이름들:
  • 휴대용 카트 배치

Given PO

다른 이름들:
  • ASTX727
  • CDA 억제제 E7727/데시타빈 조합제 ASTX727
  • 세다주리딘/데시타빈 조합제 ASTX727
  • 세다주리딘/데시타빈 정제
  • 인코비
  • C-DEC
  • 12-C
  • ASTX 727
  • ASTX-727
  • 이나코비

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Overall response rate (ORR) (Arms A and B)
기간: Up to 2 years

Defined as an objective status of complete response (CR) or partial response (PR) evaluated by Response Evaluation Criteria in Lymphoma (RECIL) criteria after 2 courses of treatment in all arms. Will be compared between the two arms. The proportion of successes will be estimated in each arm by the number of successes divided by the total number of evaluable patients. Exact binomial ninety-five percent confidence intervals for the true success proportion will be calculated in each arm. For the diffuse large B-cell lymphoma (DLBCL) arms, comparison of overall response rates between the two treatment groups will be performed using a one-sided chi-square test at significance level 0.10.

Up to 2 years
ORR (Arm C)
기간: Up to 2 years

Defined as an objective status of CR or PR evaluated by RECIL criteria after 2 cycles of treatment. The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. Exact binomial ninety-five percent confidence intervals for the true success proportion will be calculated in each arm.

Up to 2 years
Hematologic response (HI) rate (Arm D)
기간: At 20 weeks

Defined as an objective status of HI-E (minor or major response), HI-P, or HI-N evaluated by Myelodysplastic Syndrome International Working Group (IWIG) 2018 criteria at 20 weeks. Exact binomial ninety-five percent confidence intervals for the true success proportion will be calculated in each arm.

At 20 weeks
Overall Response Rate (ORR) in Arm E
기간: At completion of cycle 4 (each cycle is 21 days)

Defined as an objective status of complete remission, complete cytogenetic remission, partial remission, bone marrow response, or clinical benefit after 4 cycles of therapy as defined by the 2015 IWG myelodysplastic syndrome/ myeloproliferative neoplasm response criteria.

At completion of cycle 4 (each cycle is 21 days)

2차 결과 측정

결과 측정
측정값 설명
기간
Clinical benefit rate (Arms A, B, and C)
기간: Up to 2 years

Will be estimated in each arm by the number of patients who achieve a CR, PR, minor response (MR), or stable disease (SD) on the cycle 2 response assessment divided by the total number of evaluable patients. Exact binomial 95% confidence intervals for the true success rate will be calculated. The clinical benefit rate will be compared between the DLBCL arms using the chi-square test (or Fisher's exact test if the data in the contingency table is sparse).

Up to 2 years
Overall survival
기간: From registration to death due to any cause, assessed up to 2 years

The distribution of overall survival will be estimated in each arm using the method of Kaplan-Meier. In the DLBCL arms, the comparison of overall survival between the two treatment arms will be based on the log-rank test.

From registration to death due to any cause, assessed up to 2 years
Progression-free survival
기간: From date of first treatment to the earliest date of documentation of disease progression or death due to any cause, assessed up to 2 years

The distribution of progression-free survival will be estimated in each arm using the method of Kaplan-Meier. In the DLBCL arms, the comparison of progression-free survival between the two treatment arms will be based on the log-rank test.

From date of first treatment to the earliest date of documentation of disease progression or death due to any cause, assessed up to 2 years
Percent of transplant eligible patients proceeding to transplant (Arms A, B and C)
기간: Up to 2 years

Will be estimated in each arm by the number of patients proceeding to transplant divided by the total number of patients who were considered transplant eligible. Exact binomial 95% confidence intervals for the true success rate will be calculated. The rate will be compared between the DLBCL arms using the chi-square test (or Fisher's exact test if the data in the contingency table is sparse).

Up to 2 years
Transfusion dependency (Arm D)
기간: Up to 2 years

Transfusion dependency will be summarized descriptively. The number of patients transfusion dependent at baseline and during follow-up will be summarized.

Up to 2 years
Incidence of adverse events
기간: Up to 2 years

Assessed using Common Terminology Criteria for Adverse Events (CTCAE). The maximum grade for each type of adverse event will be recorded for each patient, and frequency tables will be reviewed to determine patterns. Additionally, the relationship of the adverse event(s) to the study treatment will be taken into consideration. In the DLBCL arms, the overall adverse event rates for Grade 3 or higher hematologic and non-hematologic adverse events at least possibly related to treatment will be compared between the two treatment groups using the chi-square test (or Fisher's exact test if the data in the contingency table is sparse). The rate of febrile neutropenia will be evaluated in each arm.

Up to 2 years
Incidence of adverse events
기간: Up to 2 years

Assessed using Patient Reported Outcomes (PRO)-CTCAE (Arms A and B). PRO-CTCAE scores range from 0-4, with corresponding response choices for frequency (Never / Rarely / Occasionally / Frequently / Almost constantly), for severity (None / Mild / Moderate / Severe / Very severe) and interference (Not at all / A little bit / Somewhat / Quite a bit / Very much). The scores for each type of adverse event will be recorded for each patient, and frequency tables will be reviewed to determine patterns. PRO-CTCAE scores will be compared between the two treatment groups using the chi-square test (or Fisher's exact test if the data in the contingency table is sparse).

Up to 2 years
Continued salvage therapy beyond cycle 2 (Arm A, B and C)
기간: Up to 2 years

Will be assessed by evaluating the number of patients who achieve an improved response after cycle 4 compared to the cycle 2 assessment in patients who received additional cycles of ascorbic acid/placebo added to salvage therapy beyond cycle 2. In addition, the number of patients who changed salvage therapies after cycle 2 will be assessed. This analysis will be primarily descriptive.

Up to 2 years
Clinical benefit rate (Arm E)
기간: Up to 2 years

The rates of complete response, complete cytogenetic remission, partial remission, marrow response, and clinical benefit will be estimated by the number of patients with each response type divided by the number of evaluable patients.

Up to 2 years
Hematologic response rate in Arm E
기간: Up to 2 years

The rates of erythroid response, platelet response, neutrophil response, spleen response and symptom response will be estimated by the number of patients with each response type divided by the number of evaluable patients.

Up to 2 years

기타 결과 측정

결과 측정
측정값 설명
기간
Biomarker analysis on blood and tissue (Arms A, B, and C)
기간: Baseline up to 2 years

Will consider the correlative research exploratory.

Baseline up to 2 years
Biomarker analysis (Arm D)
기간: Baseline up to 2 years

Variant allele frequency (VAF), biomarkers levels from Olink study, values of the cytokines, endothelial dysfunction, inflammation markers and levels of 5mc/5hmc will be measured at baseline, after completion of treatment (at 20 weeks), and at one-year post-registration. Values will be summarized graphically and descriptively at each time point and changes across time will be explored. Due to small sample size, these correlative analyses will be considered exploratory.

Baseline up to 2 years
Molecular response (Arm D)
기간: Up to 2 years

Defined as a 2 standard deviation reduction in VAF from baseline VAF. Exact binomial 95% confidence intervals for the true success rate will be calculated.

Up to 2 years
TET2 activity (Arm D)
기간: At baseline and weeks 12, 20, 52

Values will be summarized graphically and descriptively at each time point and changes across time will be explored.

At baseline and weeks 12, 20, 52

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 수석 연구원: Thomas E Witzig, M.D., Mayo Clinic

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2018년 3월 23일

기본 완료 (추정된)

2031년 2월 22일

연구 완료 (추정된)

2033년 11월 2일

연구 등록 날짜

최초 제출

2018년 1월 25일

QC 기준을 충족하는 최초 제출

2018년 1월 25일

처음 게시됨 (실제)

2018년 2월 1일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 28일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 24일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

추가 관련 MeSH 약관

기타 연구 ID 번호

  • LS1781
  • P50CA097274 (미국 NIH 보조금/계약)
  • LS1781 (기타 식별자: Mayo Clinic in Rochester)
  • NCI-2018-00057 (레지스트리 식별자: CTRP (Clinical Trial Reporting Program))
  • 17-008096 (기타 식별자: Mayo Clinic Institutional Review Board)

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다